<p>, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) 今天宣布，2025 年 12 月 16 日，公司批准了非法定股票期权，购买总计 3,825 股普通股和 4,385 个限制性股票单位（&#34;RSUs&#34;），每个单位代表在归属时获得一股普通股的权利，授予五名新员工。这些奖励是根据纳斯达克诱导授予例外条款作为新员工薪酬的一部分。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2582388/PTC_LOGO_Logo_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2582388/PTC_LOGO_Logo_Logo.jpg"/></p>
<p>这些诱导授予于 2025 年 12 月 16 日获得 PTC 薪酬委员会的批准，并作为每位员工接受公司雇佣的诱导材料，根据纳斯达克上市规则 5635(c)(4) 进行。</p>
<p>所有股票期权的行使价格为每股 75.42 美元，这是 2025 年 12 月 16 日 PTC 普通股的收盘价。股票期权的有效期为 10 年，并在四年内归属，适用员工的新雇佣日期的第一周年时，原始股份数量的 25% 归属，之后每个三个月期末归属原始股份数量的 6.25%，直到完全归属，前提是员工在适用的归属日期继续为公司服务。RSUs 将在四年内归属，适用员工的新雇佣日期的每个周年时，原始股份数量的 25% 归属，直到完全归属，前提是员工在适用的归属日期继续为公司服务。</p>
<p><strong>关于 PTC Therapeutics, Inc.</strong> PTC 是一家全球生物制药公司，致力于为生活在罕见疾病中的儿童和成人发现、开发和商业化临床差异化药物。PTC 正在推进一条强大而多样化的变革性药物管线，作为其使命的一部分，旨在为有未满足医疗需求的患者提供最佳治疗方案。公司的战略是利用其科学专业知识和全球商业基础设施，为患者和其他利益相关者优化价值。要了解更多关于 PTC 的信息，请访问 www.ptcbio.com，并在 LinkedIn、X、Facebook 和 Instagram 上关注我们。</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p><strong>投资者：</strong> Ellen Cavaleri</p>
<p>+1 (615) 618-8228</p>
<p>ecavaleri@ptcbio.com</p>
<p><strong>媒体：</strong> Jeanine Clemente</p>
<p>+1 (908) 912-9406</p>
<p>jclemente@ptcbio.com</p>
<p>来源 PTC Therapeutics, Inc.</p>

PTCT

<p>PTC Therapeutics 宣布根据纳斯达克上市规则 5635(c)(4) 向五名新员工授予诱导性补偿。该补偿包括 3,825 股的非法定股票期权和 4,385 个限制性股票单位（RSUs）。股票期权的有效期为 10 年，分四年归属，行使价格为每股 75.42 美元。RSUs 也在四年内归属。这些补偿是新员工薪酬的一部分</p>

<p>, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 3,825 shares of its common stock and 4,385 restricted stock units (&#34;RSUs&#34;), each representing the right to receive one share of its common stock upon vesting, to five new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) 今天宣布，2025 年 12 月 16 日，公司批准了非法定股票期权，购买总计 3,825 股普通股和 4,385 个限制性股票单位（&#34;RSUs&#34;），每个单位代表在归属时获得一股普通股的权利，授予五名新员工。这些奖励是根据纳斯达克诱导授予例外条款作为新员工薪酬的一部分。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2582388/PTC_LOGO_Logo_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2582388/PTC_LOGO_Logo_Logo.jpg"/></p>
<p>The inducement grants were approved by PTC's Compensation Committee on Dec. 16, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>这些诱导授予于 2025 年 12 月 16 日获得 PTC 薪酬委员会的批准，并作为每位员工接受公司雇佣的诱导材料，根据纳斯达克上市规则 5635(c)(4) 进行。</p>
</div><p>All stock option awards have an exercise price of $75.42 per share, the closing price of PTC's common stock on Dec. 16, 2025, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.</p>
<div class="lb-trans"><p>所有股票期权的行使价格为每股 75.42 美元，这是 2025 年 12 月 16 日 PTC 普通股的收盘价。股票期权的有效期为 10 年，并在四年内归属，适用员工的新雇佣日期的第一周年时，原始股份数量的 25% 归属，之后每个三个月期末归属原始股份数量的 6.25%，直到完全归属，前提是员工在适用的归属日期继续为公司服务。RSUs 将在四年内归属，适用员工的新雇佣日期的每个周年时，原始股份数量的 25% 归属，直到完全归属，前提是员工在适用的归属日期继续为公司服务。</p>
</div><p><strong>About PTC Therapeutics, Inc.</strong> PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook, and Instagram.</p>
<div class="lb-trans"><p><strong>关于 PTC Therapeutics, Inc.</strong> PTC 是一家全球生物制药公司，致力于为生活在罕见疾病中的儿童和成人发现、开发和商业化临床差异化药物。PTC 正在推进一条强大而多样化的变革性药物管线，作为其使命的一部分，旨在为有未满足医疗需求的患者提供最佳治疗方案。公司的战略是利用其科学专业知识和全球商业基础设施，为患者和其他利益相关者优化价值。要了解更多关于 PTC 的信息，请访问 www.ptcbio.com，并在 LinkedIn、X、Facebook 和 Instagram 上关注我们。</p>
</div><p><strong>For more information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p><strong>Investors:</strong> Ellen Cavaleri</p>
<div class="lb-trans"><p><strong>投资者：</strong> Ellen Cavaleri</p>
</div><p>+1 (615) 618-8228</p>
<div class="lb-trans"><p>+1 (615) 618-8228</p>
</div><p>ecavaleri@ptcbio.com</p>
<div class="lb-trans"><p>ecavaleri@ptcbio.com</p>
</div><p><strong>Media:</strong> Jeanine Clemente</p>
<div class="lb-trans"><p><strong>媒体：</strong> Jeanine Clemente</p>
</div><p>+1 (908) 912-9406</p>
<div class="lb-trans"><p>+1 (908) 912-9406</p>
</div><p>jclemente@ptcbio.com</p>
<div class="lb-trans"><p>jclemente@ptcbio.com</p>
</div><p>SOURCE PTC Therapeutics, Inc.</p>
<div class="lb-trans"><p>来源 PTC Therapeutics, Inc.</p>
</div>

PTC Therapeutics 根据纳斯达克上市规则 5635(c)(4) 报告了诱导性授予 | PTCT 股票新闻